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Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about
malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised
immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-
ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5,
and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the
tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly,
treatment with the DNA hypomethylating agent 5-aza-2'-deoxycytidine induced and up-regulated the expression of the
cancer/testis antigen examined in malignant mesothelioma cells. Overall, these ﬁndings strongly suggest that cancer/testis
antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the
clinical use of 5-aza-2'-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.
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No conventional therapy prolongs survival of malignant mesothe-
lioma (MM) patients (Lee et al, 2000); however, immunotherapy
may have a positive impact in the treatment of MM. In fact,
MM cells can present recall antigens to the immune system (Mutti
et al, 1998), and systemic administration of IL-12 generated
immune responses to MM in murine models (Caminschi et al,
1998). Additionally, tumour-reactive antibodies were detected in
sera of MM patients (Robinson et al, 1998), and non-speciﬁc
immunotherapy showed some clinical efﬁcacy in human MM
(Castagneto et al, 2001). Despite these evidences, little is known
about MM-associated tumour antigens that may represent useful
therapeutic targets to implement immunotherapeutic approaches
in MM patients.
Among known immunogenic tumour-associated antigens (TAA)
(for review see Traversari, 1999), cancer testis antigens (CTA)
including MAGE, GAGE and SSX gene families, and NY-ESO-1,
are expressed in solid tumours of different histotype but not in
normal tissues except testis (Traversari, 1999). Due to their unique
tissue distribution, and recognition by cytotoxic T lymphocytes
(CTL) and/or by B lymphocytes, CTA represent useful therapeutic
targets in solid malignancies (Traversari, 1999).
To extend to MM patients CTA-based immunotherapeutic
approaches that are proving promising in solid tumours (Marc-
hand et al, 1999; Nishiyama et al, 2001), we analysed the
expression of well-characterised CTA by mesothelial and MM
cells.
Furthermore, due to the demonstrated role of DNA methylation
in regulating gene expression (Jones and Takai, 2001), and since
promoter methylation is involved in the expression of MAGE genes
in human melanoma (De Smet et al, 1996, 1999; Sigalotti et al,
2002), we investigated the role of the DNA hypomethylating agent
5-aza-2'-deoxycytidine (5-AZA-CdR) in regulating the differential
distribution of CTA and their constitutive levels of expression in
MM.
Our results provide the ﬁrst evidence that different CTA can be
co-expressed in and among MM specimens, and also highlight that
DNA methylation accounts for their heterogeneous distribution in
individual MM tissues.
MATERIALS AND METHODS
Mesothelial and mesothelioma cells and 5-AZA-CdR
treatment
Primary and long-term cultures of MM cells from pleural effusion
of MM patients, and cultures of mesothelial cells from pleural effu-
sion of patients with heart failure were obtained and grown as
previously described (Mutti et al, 1998). Primary cultures were
utilised between the second and third passage in vitro. Treatment
with 5-AZA-CdR (Sigma Chemical Co., St. Louis, MO, USA)
was performed as described (Coral et al, 1999).
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The anti-NY-ESO-1 mAb ES121 has been previously described
(Jungbluth et al, 2001). The anti-NY-ESO-1 rabbit antiserum was
obtained from 20-week-old NZW female rabbit immunised at
weekly intervals with subcutaneous injections of 1 mg of recombi-
nant NY-ESO-1 protein. Immunoprecipitation, SDS–PAGE, and
Western blotting were performed as described (Maio et al, 1991).
Reverse transcription (RT) polymerase chain reaction
(PCR) analysis and competitive PCR
Total RNA extraction and RT–PCR reactions were performed as
described (Coral et al, 1999). Oligonucleotide primer sequences
and gene-speciﬁc PCR ampliﬁcation programs utilised have been
deﬁned for MAGE-1, -2, -3, -4 (Brasseur et al, 1995), NY-ESO-1
(Ja ¨ger et al, 1998), GAGE 1-2 (Van den Eynde et al, 1995), GAGE
1-6 (Van den Eynde et al, 1995), SSX 1-5 (dos Santos et al, 2000),
SSX-2 (Sahin et al, 2000), RAGE-1 (Neumann et al, 1998), tyrosi-
nase and Melan-A/MART-1 (van Elsas et al, 1996). The integrity of
each RNA and oligo-dT-synthesised cDNA sample was conﬁrmed
by the ampliﬁcation of the b-actin housekeeping gene (Coral et
al, 1999). Ten ml of each RT–PCR sample were run on a 2%
agarose gel and visualised by ethidium bromide staining.
The level of expression of distinct antigens was scored according
to the intensity of the speciﬁc RT–PCR product, which was
obtained by densitometric analysis of ethidium bromide-stained
agarose gels using a Gel Doc 2000 documentation system and
the QuantityOne densitometric analysis software (Bio-Rad, Milan,
Italy). The intensity of RT–PCR products were compared to that
of the reference human melanoma cell line Mel 142 (MAGE-1-,
-2-, -3-, -4-, GAGE 1-2-, GAGE 1-6-, SSX-2- and SSX 1-5-positive)
or human ﬁbrosarcoma cell line HT1080 (NY-ESO-1-positive) or
human renal cell carcinoma cell line LE9211 (RAGE-1-positive).
Samples were scored 7, no RT–PCR product detectable; +,
expression level 510% to that of the appropriate reference cell
line; ++, expression level 410% to that of the appropriate refer-
ence cell line. Competitive PCR for MAGE-3 and b-actin was
performed as described (Sigalotti et al, 2002).
RESULTS
CTA expression in mesothelial and MM cells
Three primary cultures (MES-CM98, MES-MM98, and MES-
OC99) and three long-term cultures (MPP-89, MES-1, and MES-
2) of MM cells were analysed for their constitutive expression of
MAGE-1, -2, -3, -4, NY-ESO-1, GAGE 1-2, GAGE 1-6, SSX-2,
and SSX 1-5. RT–PCR analysis revealed frequent expression of
CTA belonging to the MAGE, GAGE and SSX gene families; in
contrast, a reduced frequency of MAGE-4, and NY-ESO-1 was
found (Table 1). None of the CTA examined were detected in
mesothelial cells (Table 1).
Noteworthy, four out of six MM cells investigated expressed the
TAA RAGE-1 (Table 1), and its expression was also detected in
three different primary cultures of mesothelial cells (representative
results are reported in Table 1).
Consistent with their classiﬁcation as melanocyte differentiation
antigens, no expression of Melan-A/MART-1 and tyrosinase was
detected in mesothelial and MM cells (data not shown).
Induction and up-regulation of CTA expression by
5-AZA-CdR in MM cells
In order to determine whether DNA methylation could account for
the heterogeneous expression of CTA in MM, RT–PCR analysis of
CTA expression was performed on total RNA from MPP-89, MES-
MM98, MES-OC99, MES-1, and MES-2 MM cells, treated with the
DNA hypomethylating agent 5-AZA-CdR and compared with
untreated controls. Treatment with 5-AZA-CdR consistently
induced the expression of MAGE-1, -2, -3 and -4, NY-ESO-1,
and SSX-2 in MM cells constitutively negative for one or more
of these CTA (Table 2, Figure 1), with the exception of MAGE-3
in MES-1 MM cells (Table 2). Furthermore, the intensity of
RT–PCR products for CTA that were constitutively expressed by
MM cells was invariantly higher in 5-AZA-CdR-treated cells (Table
2, Figure 1). Consistently, competitive RT–PCR analysis revealed
a six to 10-fold increase in MAGE-3 expression in 5-AZA-CdR-
treated MPP-89 and MES-OC99 cells, respectively. As expected,
no induction of Melan-A/MART-1 expression was observed follow-
ing 5-AZA-CdR treatment in MM cells (data not shown).
Biochemical analysis of NY-ESO-1 expressed by
5-AZA-CdR-treated MM cells
To assess whether the induction/up-regulation of CTA expression
observed at mRNA level was followed by the production of the
respective protein, immunoprecipitation and Western blotting for
NY-ESO-1 were performed on MPP-89 and MES-CM98 MM cells,
treated or not with 5-AZA-CdR. 5-AZA-CdR strongly up-regulated
the expression of NY-ESO-1 protein in MPP-89 MM cells (Figure
1), and induced de novo expression of NY-ESO-1 protein in MES-
CM98 MM cells (Figure 1). Noteworthy, the molecular weight of
NY-ESO-1 expressed by 5-AZA-CdR-treated MPP-89 and MES-
CM98 MM cells was identical to that of NY-ESO-1 constitutively
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Table 1 RT–PCR analysis of TAA expressed in mesothelial and MM cells
MM cells
Mesothelial MES- MES- MES-
cells MPP-89 CM98 MM98 OC99 MES-1 MES-2
MAGE-1 7
a + 7 ++ ++ + 7
MAGE-2 7 ++ + + 77
MAGE-3 7 ++ + ++77
MAGE-4 7 7 777 + 7
NY-ESO-1 7 + 7777 +
GAGE 1-2 7 ++ + + ++
GAGE 1-6 7 + + ++ + + +
SSX 2 7 + 77++7
SSX 1-5 7 ++ ++ ++ ++ + +
RAGE-1 ++ ++ 7 ++ + + 7
b-actin ++ ++ ++ ++ ++ ++ ++
aIntensity of RT–PCR products: 7, not detectable; +, weak; ++, strong.
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(Figure 1).
DISCUSSION
In this study we demonstrate, for the ﬁrst time, that different immu-
nogenic CTA are concomitantly but heterogeneously expressed in
and among human MM specimens. CTA belonging to the MAGE,
GAGE and SSX gene families were highly expressed in MM cells
analysed (Table 1). This pattern of CTA expression in MM is consis-
tent with the elevated frequency of MAGE family gene expression
reported in metastatic melanomas (Brasseur et al, 1995); indeed, ﬁve
out of six MM cells examined expressed MAGE-1 and/or -2, and/or
-3 genes (Table 1). Noteworthy, MAGE-3 was highly expressed by
MM cells; this ﬁnding suggests that MAGE-3, an extensively utilised
therapeutic target for cancer immunotherapy (Marchand et al, 1999;
Nishiyama et al, 2001), represents a promising candidate for CTA-
based immunotherapy in the majority of MM patients.
Interestingly, the MM cells analysed concomitantly expressed at
least four CTA (Table 1), suggesting for the possibility to vaccinate
MM patients against multiple therapeutic CTA. Such an approach
may serve to reduce the emergence of CTA–negative clones that
may escape treatment-induced immune recognition of MM cells.
However, the constitutive intratumour heterogeneity of CTA
utilised as therapeutic targets (dos Santos et al, 2000) could also
impair the clinical outcome of CTA-speciﬁc immunotherapeutic
approaches, through the emergence of CTA-negative neoplastic
clones. In this respect, the ability of 5-AZA-CdR to demethylate
genomic DNA (Razin and Riggs, 1980), resulting in the induction
or up-regulation of different CTA (Table 2, Figure 1), suggests that
its in vivo administration might revert the CTA-negative phenotype
of intratumour MM clones. The feasibility of this approach is
further supported by recent evidences indicating that CTA expres-
sion induced by 5-AZA-CdR in melanoma cells is long-lasting
(Coral et al, 1999; De Smet et al, 1999), remaining stable through-
out cellular replication (De Smet et al, 1999).
We also found that 5-AZA-CdR up-regulates the expression of
HLA class I antigens, and of the co-stimulatory molecules intercellu-
lar adhesion molecule-1 and leukocyte function-associated antigen-3
on MES-MM98 MM cells (data not shown). Thus, in vivo administra-
tion of 5-AZA-CdR, in addition to induce/up-regulate CTA
expression by MM cells, might also enhance their constitutive immu-
nogenicity through the up-regulated expression of distinct
components recognised on transformed cells by T lymphocytes.
Due to its suggested immunotherapeutic potential (Gaugler et al,
1996; Neumann et al, 1998), the distribution of the TAA RAGE-1
was also investigated. Noteworthy, RAGE-1 was expressed in all
benign and malignant mesothelial cells investigated, with the excep-
tion of MES-CM98 and MES-2 MM cells (Table 1). This pattern of
RAGE-1 expression represents a unique feature of mesothelial and
mesothelioma cells; in fact, RAGE-1 is rarely expressed in solid
malignancies, and only in the retina among normal tissues (Gaugler
et al, 1996). The distribution of RAGE-1 in benign and malignant
mesothelial cells closely resembles that of melanocyte differentiation
antigens in melanoma (Traversari, 1999), and suggests for a possible
tissue-speciﬁcity of RAGE-1 expression.
The results of this study, although preliminary, strongly suggest
that CTA-based immunotherapy may represent a suitable therapeu-
tic approach to MM, and provide the scientiﬁc background for
new and eventually more effective chemo-immunotherapeutic
approaches in MM patients.
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Table 2 RT–PCR analysis of TAA expressed by 5-AZA-CdR-treated MM cells
MPP-89 MES-MM98 MES-OC99 MES-1 MES-2
Ctrl 5-AZA-CdR Ctrl 5-AZA-CdR Ctrl 5-AZA-CdR Ctrl 5-AZA-CdR Ctrl 5-AZA-CdR
MAGE-1 +
a ++ ++ ++ ++ ++ + ++ 7 +
MAGE-2 + ++ + ++ + ++ 7 ++ 7 +
MAGE-3 + ++ + ++ + ++ 777+
MAGE-4 7 ++ 7 ++ 7 ++ + ++ 7 ++
NY-ESO-1 + ++ 7 ++ 7 ++ 7 ++ + ++
GAGE1-2 + ++ + ++ + ++ + ++ + ++
GAGE1-6 + ++ ++ ++ + ++ + ++ + ++
SSX 2 + ++ 7 + + ++ + ++ 7 ++
RAGE-1 ++ ++ ++ ++ + + + + 77
b-actin ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
aIntensity of RT–PCR products: 7, not detectable; +, weak; ++, strong.
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Figure 1 Expression of NY-ESO-1 in 5-AZA-CdR-treated MM cells. (A)
Cell lysates of MPP-89 and MES-CM98 MM cells treated (5-AZA-CdR) or
not (Ctrl) with 5-AZA-CdR for 48 h, and of NY-ESO-1-positive ﬁbrosar-
coma cells HT1080 (Ctrl+), were immunoprecipitated by an anti-NY-
ESO-1 rabbit antiserum, size-fractionated by a 13% one-dimensional
SDS–PAGE under reducing conditions, and blotted onto Hybond-C super
transfer nitrocellulose membranes. Then, membranes were incubated with
1 mgm l
71 of ES121 anti-NY-ESO-1 mAb, and further processed to be de-
veloped by the enhanced chemiluminescence technique. (B) Total RNA
was extracted from MPP-89 and MES-CM98 MM cells treated (5-AZA-
CdR) or not (Ctrl) with 5-AZA-CdR for 48 h, and from NY-ESO-1-posi-
tive ﬁbrosarcoma cells HT1080 (Ctrl+), and RT–PCR was performed
using NY-ESO-1-speciﬁc primer pair. PCR products were size-fractionated
on a 2% agarose gel and visualised by ethidium bromide staining.
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